GSK to Pay $750 Million Fine for Tainted Drugs

Oct. 26, 2010
Pleaded guilty to manufacturing and distributing adulterated drugs made at a now-closed Puerto Rico facility

British pharmaceutical giant GlaxoSmithKline has agreed to plead guilty in a tainted drug scandal and to pay a $750-million fine, the Justice Department said on Oct. 26.

Pharmco Puerto Rico, a subsidiary of GlaxoSmithKline admitted it was guilty of the charges relating to the manufacture and distribution of certain adulterated drugs made at a now-closed Puerto Rico facility, the department said.

The resolution includes a criminal fine of $150 million and a civil settlement of $600 million to the federal government and states.

Four drugs manufactured by Pharmco were deemed adulterated after they did not conform to U.S. safety requirements and did not have the "quality and purity characteristics which it purported or was represented to possess."

The drugs, manufactured at the plant between 2001 and 2005, are Kytril, Bactroban, Paxil CR and Avandamet.

The guilty plea and sentence is not final until accepted by the U.S. District Court in Boston, Massachusetts, the department said.

Copyright Agence France-Presse, 2010

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!